, Volume 3, Issue 2, pp 94–99 | Cite as

Clinical and Economic Factors in the Selection of Drugs for Gastroesophageal Reflux Disease

  • C. M. Bate
  • P. D. I. Richardson
Leading Article


Cimetidine Omeprazole Ranitidine Gastroesophageal Reflux Disease Domperidone 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bate CM, Cost-effectiveness of omeprazole in the treatment of reflux oesophagitis. British Journal of Medical Economics 1: 53–61, 1991Google Scholar
  2. Bate CM. Reflux oesophagitis. Martin Dunitz, London, England, 1992Google Scholar
  3. Bate CM, Crowe JP, Dickinson RJ, Green JRB, Bannerjee S, et al. Reflux oesophagitis resolves more rapidly with omeprazole 20mg om than with ranitidine 150mg bd; omeprazole 40mg om provides further benefit in unresponsive patients. British Journal of Clinical Research 2: 133–148, 1991Google Scholar
  4. Bate CM, Heavey DJ, McCloy R, Wilkinson SP. Gastroesophageal reflux. In Scott C (Ed.) Update Postgraduate Centre Series, Reed Healthcare, 1991Google Scholar
  5. Bate CM, Keeling PWN, O’Morain C, Wilkinson SP, Foster DN et al. Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations. Gut 31: 968–972, 1990PubMedCrossRefGoogle Scholar
  6. Bate CM, Richardson PDI. A one year model for the cost-effectiveness of treating reflux oesophagitis. British Journal of Medical Economics 2: 5–11, 1992aGoogle Scholar
  7. Bate CM, Richardson PDI. Symptomatic assessment and cost-effectiveness of treatments for reflux oesophagitis: comparisons of omeprazole and histamine H2 receptor antagonists. British Journal of Medical Economics 2: 37–48, 1992bGoogle Scholar
  8. Bramble MG. Open-access endoscopy — a nationwide survey of current practice. Gut 33: 282–285, 1992PubMedCrossRefGoogle Scholar
  9. Crean G. Causes of dyspepsia and its effective treatment. Prescriber January: 29–37, 1992Google Scholar
  10. Eriksen CA, Cuschieri A. Diagnostic tests for gastroesophageal reflux disease. In Hennessy TPJ et al. (Eds) Reflux oesophagitis, Butterworths, London 55–86, 1989Google Scholar
  11. Gear MW, Wilkinson SP. Open access upper alimentary endoscopy. British Journal of Hospital Medicine 41: 438–444, 1989PubMedGoogle Scholar
  12. Heading RC. Epidemiology of oesophageal reflux disease. Scandinavian Journal of Gastroenterology 24 (Suppl. 168): 33–37, 1989Google Scholar
  13. Hillman AL, Bloom BS, Fendrick AM, Schwartz JS. Cost and quality effects of alternative treatments for persistent gastroesophageal reflux disease. Archive of Internal Medicine 152: 1467–1472, 1992CrossRefGoogle Scholar
  14. Holt S, Howden CW. Omeprazole overview and opinion. Digestive Diseases and Sciences 36: 385–393, 1991PubMedCrossRefGoogle Scholar
  15. Stacher G, Weiss W. Diagnosis of gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology 24 (Suppl 156): 21–24, 1989CrossRefGoogle Scholar
  16. Stoker Dl, Williams JG, Leicester RC, Colin-Jones DG. Oesophagitis — a five year review. Gut 29: A1450, 1988Google Scholar
  17. Weinbeck M, Berges W. Esophageal disorders in the etiology and pathophysiology of dyspepsia. Scandinavian Journal of Gastroenterology 20 (Suppl. 109): 133–137, 1985CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 1993

Authors and Affiliations

  • C. M. Bate
    • 1
  • P. D. I. Richardson
    • 2
  1. 1.Royal Albert Edward InfirmaryWigan, LancashireEngland
  2. 2.Clinical Research DepartmentAstra Pharmaceuticals LtdKings Langley, HertfordshireEngland

Personalised recommendations